Communiqués Alembic Pharmaceuticals Limited

Actions

Temps Différé NSE India S.E. Autres places de cotation 09:10:44 06/08/2026			Varia. 5j.	Varia. 1 janv.
828,90 ^INR	+1,31%		+3,44%	-1,86%

04/08	Transcript : Alembic Pharmaceuticals Limited, Q1 2027 Earnings Call, Aug 04, 2026
04/08	Alembic Pharmaceuticals Limited publie ses résultats pour le premier trimestre clos le 30 juin 2026	CI

25/11/22	Alembic Pharmaceuticals : Schedule of Analysts/Institutional Investor Meet/Con. Call	PU
25/10/22	Alembic Pharmaceuticals : Disclosure of other UPSI/material event	PU
14/09/22	Alembic Pharmaceuticals : Amendment to AOA/MOA	PU
24/05/22	Cosette Pharmaceuticals and Alembic Pharmaceuticals Limited Announce the Approval and Launch of a National Brand Equivalent (NBE) of Abreva® (Docosanol Cream 10%) Including the First Approval in the Pump Format	BU
29/03/22	Alembic Pharmaceuticals : Amalgamation/Merger	PU
31/07/17	Alembic Pharmaceuticals : Press Release USFDA Approval Doxycycline Capsules USP	PU
21/07/17	Alembic Pharmaceuticals : Press Release April	PU
18/07/17	Alembic Pharmaceuticals : Press Release USFDA Approval Olmesartan Medoxomil & Amlodipine Tablets	PU
05/07/17	Alembic Pharmaceuticals : Press Release USFDA Tentative Approval Vardenafil Hydrochloride Orally Disintegrating Tablets	PU
22/06/17	Alembic Pharmaceuticals : Press Release USFDA Approval Amantadine Hydrochloride Capsules USP	PU
15/05/17	Alembic Pharmaceuticals : Press Release USFDA Approval Fenofibric Acid Delayed-Release Capsules	PU
03/05/17	Alembic Pharmaceuticals : Press Release January	PU
19/04/17	Alembic Pharmaceuticals : Press Release USFDA Approval Fluoxetine Hydrochloride Tablets	PU
19/04/17	Alembic Pharmaceuticals : Press Release USFDA Tentative Approval Vilazodone Tablets	PU
19/04/17	Alembic Pharmaceuticals : Press Release Successful USFDA Inspection Bioequivalence	PU